arrow
G

Gregg W. Stone

Icahn School of Medicine at Mount Sinai
H指数:194
被引数:16.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Balance of non–Lp(a) apoB and Lp(a) with Coronary Plaque Phenotypes and MACE: Insights from PROSPECT II and CASABLANCA

非Lp(a) apoB与Lp(a)的平衡与冠状动脉斑块表型及MACE的关系:来自PROSPECT II和CASABLANCA的研究启示

2026-09-260
OA
Impact of Diabetes on Outcomes of Contemporary PCI Guided by OCT vs Angiography

糖尿病对光学相干断层扫描引导的现代经皮冠状动脉介入治疗与血管造影引导的治疗结果的影响

2026-09-140
PRE
One vs twelve month aspirin after percutaneous coronary intervention for acute myocardial infarction: individual patient-data analysis of TARGET-FIRST and ULTIMATE-DAPT trials

急性心肌梗死经皮冠状动脉介入治疗后服用阿司匹林1个月与12个月的比较:TARGET-FIRST和ULTIMATE-DAPT试验的个体患者数据分析

2026-08-290
OAAI
Bivalirudin Versus Heparin in Low and Non-Low Bleeding Risk Patients Undergoing Primary PCI for STEMI

比伐卢定与肝素在低出血风险和非低出血风险患者行ST段抬高型心肌梗死直接经皮冠状动脉介入治疗中的比较

2026-08-280
PRE
2026-08-030
PRE
Estimating the Effects of MTEER in U.S. Practice

估算MTEER在美国实践中的影响

JACC
IF0
2026-06-030
PRE
Phenotypic Diversity and Outcomes of Transcatheter Mitral Repair for Secondary Mitral Regurgitation

经导管二尖瓣修复术在二尖瓣反流中的表型多样性与结果

2026-05-110
PRE
Long-Term Mortality After PCI or CABG for Left Main Stem Disease

左主干干病变经经皮冠状动脉介入治疗(PCI)或冠状动脉旁路移植术(CABG)后的长期死亡率

JACC
IF0
2026-04-280
PRE
Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial

替格瑞洛与氯吡格雷在比伐卢定治疗的ST段抬高型心肌梗死患者行经皮冠状动脉介入治疗中的比较:BRIGHT-4试验

2026-02-011
PRE
Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events

应激心脏磁共振缺血负荷与心血管事件

2025-12-050
PRE
Intravascular ultrasound-guided percutaneous coronary intervention in acute coronary syndrome stratified by the TVF-ACS risk score: the IVUS-ACS trial
2025-11-010
OA
Mechanical circulatory support in high-risk elective PCI rationale and design of the PROTECT IV trial
2025-11-012
PRE